Copyright Reports & Markets. All rights reserved.

Global Monoclonal Antibodies for Cancers Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope of Monoclonal Antibodies for Cancers
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Monoclonal Antibodies for Cancers Consumption Value by Type: 2018 Versus 2022 Versus 2029
    • 1.3.2 Rituximab
    • 1.3.3 Trastuzumab
    • 1.3.4 Bevacizumab
    • 1.3.5 Others
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Monoclonal Antibodies for Cancers Consumption Value by Application: 2018 Versus 2022 Versus 2029
    • 1.4.2 Lymphoma
    • 1.4.3 Non-small Cell Lung Cancer (NSCLC)
    • 1.4.4 Breast Cancer
    • 1.4.5 Cervical Cancer
    • 1.4.6 Others
  • 1.5 Global Monoclonal Antibodies for Cancers Market Size & Forecast
    • 1.5.1 Global Monoclonal Antibodies for Cancers Consumption Value (2018 & 2022 & 2029)
    • 1.5.2 Global Monoclonal Antibodies for Cancers Sales Quantity (2018-2029)
    • 1.5.3 Global Monoclonal Antibodies for Cancers Average Price (2018-2029)

2 Manufacturers Profiles

  • 2.1 AbbVie
    • 2.1.1 AbbVie Details
    • 2.1.2 AbbVie Major Business
    • 2.1.3 AbbVie Monoclonal Antibodies for Cancers Product and Services
    • 2.1.4 AbbVie Monoclonal Antibodies for Cancers Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.1.5 AbbVie Recent Developments/Updates
  • 2.2 Merck
    • 2.2.1 Merck Details
    • 2.2.2 Merck Major Business
    • 2.2.3 Merck Monoclonal Antibodies for Cancers Product and Services
    • 2.2.4 Merck Monoclonal Antibodies for Cancers Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.2.5 Merck Recent Developments/Updates
  • 2.3 Roche
    • 2.3.1 Roche Details
    • 2.3.2 Roche Major Business
    • 2.3.3 Roche Monoclonal Antibodies for Cancers Product and Services
    • 2.3.4 Roche Monoclonal Antibodies for Cancers Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.3.5 Roche Recent Developments/Updates
  • 2.4 Bristol Myers Squibb
    • 2.4.1 Bristol Myers Squibb Details
    • 2.4.2 Bristol Myers Squibb Major Business
    • 2.4.3 Bristol Myers Squibb Monoclonal Antibodies for Cancers Product and Services
    • 2.4.4 Bristol Myers Squibb Monoclonal Antibodies for Cancers Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.4.5 Bristol Myers Squibb Recent Developments/Updates
  • 2.5 Daiichi Sankyo
    • 2.5.1 Daiichi Sankyo Details
    • 2.5.2 Daiichi Sankyo Major Business
    • 2.5.3 Daiichi Sankyo Monoclonal Antibodies for Cancers Product and Services
    • 2.5.4 Daiichi Sankyo Monoclonal Antibodies for Cancers Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.5.5 Daiichi Sankyo Recent Developments/Updates
  • 2.6 Johnson & Johnson
    • 2.6.1 Johnson & Johnson Details
    • 2.6.2 Johnson & Johnson Major Business
    • 2.6.3 Johnson & Johnson Monoclonal Antibodies for Cancers Product and Services
    • 2.6.4 Johnson & Johnson Monoclonal Antibodies for Cancers Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.6.5 Johnson & Johnson Recent Developments/Updates
  • 2.7 Biogen
    • 2.7.1 Biogen Details
    • 2.7.2 Biogen Major Business
    • 2.7.3 Biogen Monoclonal Antibodies for Cancers Product and Services
    • 2.7.4 Biogen Monoclonal Antibodies for Cancers Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.7.5 Biogen Recent Developments/Updates
  • 2.8 Novartis
    • 2.8.1 Novartis Details
    • 2.8.2 Novartis Major Business
    • 2.8.3 Novartis Monoclonal Antibodies for Cancers Product and Services
    • 2.8.4 Novartis Monoclonal Antibodies for Cancers Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.8.5 Novartis Recent Developments/Updates
  • 2.9 Takeda Pharmaceuticals
    • 2.9.1 Takeda Pharmaceuticals Details
    • 2.9.2 Takeda Pharmaceuticals Major Business
    • 2.9.3 Takeda Pharmaceuticals Monoclonal Antibodies for Cancers Product and Services
    • 2.9.4 Takeda Pharmaceuticals Monoclonal Antibodies for Cancers Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.9.5 Takeda Pharmaceuticals Recent Developments/Updates
  • 2.10 Astellas Pharma
    • 2.10.1 Astellas Pharma Details
    • 2.10.2 Astellas Pharma Major Business
    • 2.10.3 Astellas Pharma Monoclonal Antibodies for Cancers Product and Services
    • 2.10.4 Astellas Pharma Monoclonal Antibodies for Cancers Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.10.5 Astellas Pharma Recent Developments/Updates
  • 2.11 Qilu Pharmaceutical
    • 2.11.1 Qilu Pharmaceutical Details
    • 2.11.2 Qilu Pharmaceutical Major Business
    • 2.11.3 Qilu Pharmaceutical Monoclonal Antibodies for Cancers Product and Services
    • 2.11.4 Qilu Pharmaceutical Monoclonal Antibodies for Cancers Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.11.5 Qilu Pharmaceutical Recent Developments/Updates
  • 2.12 Luye Pharma
    • 2.12.1 Luye Pharma Details
    • 2.12.2 Luye Pharma Major Business
    • 2.12.3 Luye Pharma Monoclonal Antibodies for Cancers Product and Services
    • 2.12.4 Luye Pharma Monoclonal Antibodies for Cancers Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.12.5 Luye Pharma Recent Developments/Updates
  • 2.13 Hengrui Pharmaceuticals
    • 2.13.1 Hengrui Pharmaceuticals Details
    • 2.13.2 Hengrui Pharmaceuticals Major Business
    • 2.13.3 Hengrui Pharmaceuticals Monoclonal Antibodies for Cancers Product and Services
    • 2.13.4 Hengrui Pharmaceuticals Monoclonal Antibodies for Cancers Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.13.5 Hengrui Pharmaceuticals Recent Developments/Updates
  • 2.14 Innovent
    • 2.14.1 Innovent Details
    • 2.14.2 Innovent Major Business
    • 2.14.3 Innovent Monoclonal Antibodies for Cancers Product and Services
    • 2.14.4 Innovent Monoclonal Antibodies for Cancers Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.14.5 Innovent Recent Developments/Updates

3 Competitive Environment: Monoclonal Antibodies for Cancers by Manufacturer

  • 3.1 Global Monoclonal Antibodies for Cancers Sales Quantity by Manufacturer (2018-2023)
  • 3.2 Global Monoclonal Antibodies for Cancers Revenue by Manufacturer (2018-2023)
  • 3.3 Global Monoclonal Antibodies for Cancers Average Price by Manufacturer (2018-2023)
  • 3.4 Market Share Analysis (2022)
    • 3.4.1 Producer Shipments of Monoclonal Antibodies for Cancers by Manufacturer Revenue ($MM) and Market Share (%): 2022
    • 3.4.2 Top 3 Monoclonal Antibodies for Cancers Manufacturer Market Share in 2022
    • 3.4.2 Top 6 Monoclonal Antibodies for Cancers Manufacturer Market Share in 2022
  • 3.5 Monoclonal Antibodies for Cancers Market: Overall Company Footprint Analysis
    • 3.5.1 Monoclonal Antibodies for Cancers Market: Region Footprint
    • 3.5.2 Monoclonal Antibodies for Cancers Market: Company Product Type Footprint
    • 3.5.3 Monoclonal Antibodies for Cancers Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Monoclonal Antibodies for Cancers Market Size by Region
    • 4.1.1 Global Monoclonal Antibodies for Cancers Sales Quantity by Region (2018-2029)
    • 4.1.2 Global Monoclonal Antibodies for Cancers Consumption Value by Region (2018-2029)
    • 4.1.3 Global Monoclonal Antibodies for Cancers Average Price by Region (2018-2029)
  • 4.2 North America Monoclonal Antibodies for Cancers Consumption Value (2018-2029)
  • 4.3 Europe Monoclonal Antibodies for Cancers Consumption Value (2018-2029)
  • 4.4 Asia-Pacific Monoclonal Antibodies for Cancers Consumption Value (2018-2029)
  • 4.5 South America Monoclonal Antibodies for Cancers Consumption Value (2018-2029)
  • 4.6 Middle East and Africa Monoclonal Antibodies for Cancers Consumption Value (2018-2029)

5 Market Segment by Type

  • 5.1 Global Monoclonal Antibodies for Cancers Sales Quantity by Type (2018-2029)
  • 5.2 Global Monoclonal Antibodies for Cancers Consumption Value by Type (2018-2029)
  • 5.3 Global Monoclonal Antibodies for Cancers Average Price by Type (2018-2029)

6 Market Segment by Application

  • 6.1 Global Monoclonal Antibodies for Cancers Sales Quantity by Application (2018-2029)
  • 6.2 Global Monoclonal Antibodies for Cancers Consumption Value by Application (2018-2029)
  • 6.3 Global Monoclonal Antibodies for Cancers Average Price by Application (2018-2029)

7 North America

  • 7.1 North America Monoclonal Antibodies for Cancers Sales Quantity by Type (2018-2029)
  • 7.2 North America Monoclonal Antibodies for Cancers Sales Quantity by Application (2018-2029)
  • 7.3 North America Monoclonal Antibodies for Cancers Market Size by Country
    • 7.3.1 North America Monoclonal Antibodies for Cancers Sales Quantity by Country (2018-2029)
    • 7.3.2 North America Monoclonal Antibodies for Cancers Consumption Value by Country (2018-2029)
    • 7.3.3 United States Market Size and Forecast (2018-2029)
    • 7.3.4 Canada Market Size and Forecast (2018-2029)
    • 7.3.5 Mexico Market Size and Forecast (2018-2029)

8 Europe

  • 8.1 Europe Monoclonal Antibodies for Cancers Sales Quantity by Type (2018-2029)
  • 8.2 Europe Monoclonal Antibodies for Cancers Sales Quantity by Application (2018-2029)
  • 8.3 Europe Monoclonal Antibodies for Cancers Market Size by Country
    • 8.3.1 Europe Monoclonal Antibodies for Cancers Sales Quantity by Country (2018-2029)
    • 8.3.2 Europe Monoclonal Antibodies for Cancers Consumption Value by Country (2018-2029)
    • 8.3.3 Germany Market Size and Forecast (2018-2029)
    • 8.3.4 France Market Size and Forecast (2018-2029)
    • 8.3.5 United Kingdom Market Size and Forecast (2018-2029)
    • 8.3.6 Russia Market Size and Forecast (2018-2029)
    • 8.3.7 Italy Market Size and Forecast (2018-2029)

9 Asia-Pacific

  • 9.1 Asia-Pacific Monoclonal Antibodies for Cancers Sales Quantity by Type (2018-2029)
  • 9.2 Asia-Pacific Monoclonal Antibodies for Cancers Sales Quantity by Application (2018-2029)
  • 9.3 Asia-Pacific Monoclonal Antibodies for Cancers Market Size by Region
    • 9.3.1 Asia-Pacific Monoclonal Antibodies for Cancers Sales Quantity by Region (2018-2029)
    • 9.3.2 Asia-Pacific Monoclonal Antibodies for Cancers Consumption Value by Region (2018-2029)
    • 9.3.3 China Market Size and Forecast (2018-2029)
    • 9.3.4 Japan Market Size and Forecast (2018-2029)
    • 9.3.5 Korea Market Size and Forecast (2018-2029)
    • 9.3.6 India Market Size and Forecast (2018-2029)
    • 9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
    • 9.3.8 Australia Market Size and Forecast (2018-2029)

10 South America

  • 10.1 South America Monoclonal Antibodies for Cancers Sales Quantity by Type (2018-2029)
  • 10.2 South America Monoclonal Antibodies for Cancers Sales Quantity by Application (2018-2029)
  • 10.3 South America Monoclonal Antibodies for Cancers Market Size by Country
    • 10.3.1 South America Monoclonal Antibodies for Cancers Sales Quantity by Country (2018-2029)
    • 10.3.2 South America Monoclonal Antibodies for Cancers Consumption Value by Country (2018-2029)
    • 10.3.3 Brazil Market Size and Forecast (2018-2029)
    • 10.3.4 Argentina Market Size and Forecast (2018-2029)

11 Middle East & Africa

  • 11.1 Middle East & Africa Monoclonal Antibodies for Cancers Sales Quantity by Type (2018-2029)
  • 11.2 Middle East & Africa Monoclonal Antibodies for Cancers Sales Quantity by Application (2018-2029)
  • 11.3 Middle East & Africa Monoclonal Antibodies for Cancers Market Size by Country
    • 11.3.1 Middle East & Africa Monoclonal Antibodies for Cancers Sales Quantity by Country (2018-2029)
    • 11.3.2 Middle East & Africa Monoclonal Antibodies for Cancers Consumption Value by Country (2018-2029)
    • 11.3.3 Turkey Market Size and Forecast (2018-2029)
    • 11.3.4 Egypt Market Size and Forecast (2018-2029)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
    • 11.3.6 South Africa Market Size and Forecast (2018-2029)

12 Market Dynamics

  • 12.1 Monoclonal Antibodies for Cancers Market Drivers
  • 12.2 Monoclonal Antibodies for Cancers Market Restraints
  • 12.3 Monoclonal Antibodies for Cancers Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry
  • 12.5 Influence of COVID-19 and Russia-Ukraine War
    • 12.5.1 Influence of COVID-19
    • 12.5.2 Influence of Russia-Ukraine War

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Monoclonal Antibodies for Cancers and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Monoclonal Antibodies for Cancers
  • 13.3 Monoclonal Antibodies for Cancers Production Process
  • 13.4 Monoclonal Antibodies for Cancers Industrial Chain

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Monoclonal Antibodies for Cancers Typical Distributors
  • 14.3 Monoclonal Antibodies for Cancers Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Monoclonal Antibodies for Cancers market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period.
    Monoclonal antibodies (also called moAbs or mAbs) are proteins made in laboratories that act like proteins called antibodies in our bodies At present, monoclonal antibody drugs have become the main treatment drugs for major difficult diseases such as tumors and autoimmune diseases.
    The Global Info Research report includes an overview of the development of the Monoclonal Antibodies for Cancers industry chain, the market status of Lymphoma (Rituximab, Trastuzumab), Non-small Cell Lung Cancer (NSCLC) (Rituximab, Trastuzumab), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Monoclonal Antibodies for Cancers.
    Regionally, the report analyzes the Monoclonal Antibodies for Cancers markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Monoclonal Antibodies for Cancers market, with robust domestic demand, supportive policies, and a strong manufacturing base.
    Key Features:
    The report presents comprehensive understanding of the Monoclonal Antibodies for Cancers market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Monoclonal Antibodies for Cancers industry.
    The report involves analyzing the market at a macro level:
    Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., Rituximab, Trastuzumab).
    Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Monoclonal Antibodies for Cancers market.
    Regional Analysis: The report involves examining the Monoclonal Antibodies for Cancers market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
    Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Monoclonal Antibodies for Cancers market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
    The report also involves a more granular approach to Monoclonal Antibodies for Cancers:
    Company Analysis: Report covers individual Monoclonal Antibodies for Cancers manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
    Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Monoclonal Antibodies for Cancers This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Lymphoma, Non-small Cell Lung Cancer (NSCLC)).
    Technology Analysis: Report covers specific technologies relevant to Monoclonal Antibodies for Cancers. It assesses the current state, advancements, and potential future developments in Monoclonal Antibodies for Cancers areas.
    Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Monoclonal Antibodies for Cancers market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
    Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
    Market Segmentation
    Monoclonal Antibodies for Cancers market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
    Market segment by Type
    Rituximab
    Trastuzumab
    Bevacizumab
    Others
    Market segment by Application
    Lymphoma
    Non-small Cell Lung Cancer (NSCLC)
    Breast Cancer
    Cervical Cancer
    Others
    Major players covered
    AbbVie
    Merck
    Roche
    Bristol Myers Squibb
    Daiichi Sankyo
    Johnson & Johnson
    Biogen
    Novartis
    Takeda Pharmaceuticals
    Astellas Pharma
    Qilu Pharmaceutical
    Luye Pharma
    Hengrui Pharmaceuticals
    Innovent
    Market segment by region, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Monoclonal Antibodies for Cancers product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Monoclonal Antibodies for Cancers, with price, sales, revenue and global market share of Monoclonal Antibodies for Cancers from 2018 to 2023.
    Chapter 3, the Monoclonal Antibodies for Cancers competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Monoclonal Antibodies for Cancers breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
    Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Monoclonal Antibodies for Cancers market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
    Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Monoclonal Antibodies for Cancers.
    Chapter 14 and 15, to describe Monoclonal Antibodies for Cancers sales channel, distributors, customers, research findings and conclusion.

    Buy now